Cargando…
Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor, and surgical resection is the first choice for the treatment of the disease, but since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib (IM), the prognosis of the disease has undergone revolutionary changes....
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804055/ https://www.ncbi.nlm.nih.gov/pubmed/33456310 http://dx.doi.org/10.2147/OTT.S279998 |
_version_ | 1783636079309488128 |
---|---|
author | Xu, Hao Liu, Qi |
author_facet | Xu, Hao Liu, Qi |
author_sort | Xu, Hao |
collection | PubMed |
description | Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor, and surgical resection is the first choice for the treatment of the disease, but since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib (IM), the prognosis of the disease has undergone revolutionary changes. According to the current version of the guidelines, most GIST patients receive a fixed dose without taking into account their own individual differences, resulting in a wide difference in blood concentration, adverse reactions and prognosis. With more studies on the relationship between blood drug concentrations and prognosis, the concept of individualized therapy has been paid more attention by researchers. Therapeutic drug monitoring (TDM) has also been made available for the research field of GIST targeted therapy. How to reduce the incidence of drug resistance and adverse reactions in patients with GISTs has become the focus of the current research. This article reviews the common monitoring methods and timing of TKIs blood concentration, the reasonable range of blood drug concentration, the toxic or adverse effects caused by high blood drug concentration, some possible factors affecting blood drug concentration and recent research progress, in order to discuss and summarize the treatment strategy of individual blood drug concentration, improve the prognosis of patients and reduce the adverse effects as much as possible. |
format | Online Article Text |
id | pubmed-7804055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-78040552021-01-14 Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors Xu, Hao Liu, Qi Onco Targets Ther Review Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor, and surgical resection is the first choice for the treatment of the disease, but since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib (IM), the prognosis of the disease has undergone revolutionary changes. According to the current version of the guidelines, most GIST patients receive a fixed dose without taking into account their own individual differences, resulting in a wide difference in blood concentration, adverse reactions and prognosis. With more studies on the relationship between blood drug concentrations and prognosis, the concept of individualized therapy has been paid more attention by researchers. Therapeutic drug monitoring (TDM) has also been made available for the research field of GIST targeted therapy. How to reduce the incidence of drug resistance and adverse reactions in patients with GISTs has become the focus of the current research. This article reviews the common monitoring methods and timing of TKIs blood concentration, the reasonable range of blood drug concentration, the toxic or adverse effects caused by high blood drug concentration, some possible factors affecting blood drug concentration and recent research progress, in order to discuss and summarize the treatment strategy of individual blood drug concentration, improve the prognosis of patients and reduce the adverse effects as much as possible. Dove 2021-01-05 /pmc/articles/PMC7804055/ /pubmed/33456310 http://dx.doi.org/10.2147/OTT.S279998 Text en © 2020 Xu and Liu. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Xu, Hao Liu, Qi Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors |
title | Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors |
title_full | Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors |
title_fullStr | Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors |
title_full_unstemmed | Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors |
title_short | Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors |
title_sort | individualized management of blood concentration in patients with gastrointestinal stromal tumors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804055/ https://www.ncbi.nlm.nih.gov/pubmed/33456310 http://dx.doi.org/10.2147/OTT.S279998 |
work_keys_str_mv | AT xuhao individualizedmanagementofbloodconcentrationinpatientswithgastrointestinalstromaltumors AT liuqi individualizedmanagementofbloodconcentrationinpatientswithgastrointestinalstromaltumors |